What risk‑stratification score should be used for acute myocardial infarction in the emergency department and how is it applied?

Risk Stratification Scoring for Acute MI in the Emergency Department

Use the GRACE Risk Score or TIMI Risk Score for risk stratification of patients with confirmed or suspected acute coronary syndrome in the ED, with GRACE demonstrating superior performance for predicting death or MI compared to physician judgment alone. 1

Primary Risk Stratification Tools

The 2025 ACC/AHA/ACEP guidelines explicitly recommend two well-validated scoring systems for ACS patients 1:

GRACE Risk Score (2.0) - Preferred for comprehensive risk assessment

• Target population: All ACS patients (STEMI and NSTE-ACS)
• Predicts: In-hospital, 6-month, 1-year, and 3-year death or death/MI
• Variables include:
  • Age
  • Killip class
  • Systolic blood pressure
  • Heart rate
  • ST-segment deviation
  • Cardiac arrest on admission
  • Serum creatinine
  • Elevated cardiac biomarkers

Key advantage: GRACE has been demonstrated superior to subjective physician assessment for predicting death or MI in STEMI and intermediate-risk NSTE-ACS patients 1

TIMI Risk Scores - Simpler, faster calculation

For Unstable Angina/NSTEMI:

• Predicts: 14-day all-cause death, MI, or urgent revascularization
• Score 1 point each for:
  • Age ≥65 years
  • ≥3 CAD risk factors
  • Known coronary stenosis ≥50%
  • ST-segment deviation ≥0.5 mm
  • ≥2 anginal events in prior 24 hours
  • Aspirin use in prior 7 days
  • Elevated cardiac biomarkers

For STEMI:

• Predicts: 30-day all-cause death
• Variables: Age categories, Killip class, systolic BP <100 mmHg, heart rate >100 bpm, anterior STEMI or LBBB, diabetes/hypertension/angina, weight <67 kg, time to treatment >4 hours 1

Critical Implementation Points

These scores are NOT diagnostic tools 1

• Only use for risk stratification in suspected or confirmed ACS
• Do not use to diagnose ACS initially
• Must be combined with ECG and high-sensitivity troponin results

Integration with Clinical Decision Pathways

The HEART score is increasingly recognized as superior for undifferentiated chest pain in the ED (before ACS diagnosis is established) 2:

• Specifically designed for ED chest pain evaluation
• More accurate than historical TIMI/GRACE scores for this population
• HEART score ≤3 identifies very low-risk patients suitable for early discharge 3, 4

Algorithmic Approach

Step 1: Obtain 12-lead ECG within 10 minutes of ED arrival 5, 6

Step 2: Measure high-sensitivity cardiac troponin at presentation 1

Step 3: Risk stratify based on presentation:

• If ACS not yet confirmed: Use HEART score for initial triage

  • HEART ≤3: Very low risk, consider discharge with outpatient follow-up
  • HEART 4-6: Intermediate risk, serial troponins and observation
  • HEART ≥7: High risk, admit and treat as ACS

• If ACS confirmed/highly suspected: Apply GRACE or TIMI scores

  • Guides intensity of monitoring and therapeutic interventions
  • Informs discussions about invasive vs. conservative strategy

Step 4: Serial troponin measurements

• With high-sensitivity assays: Repeat at 1-2 hours
• With conventional assays: Repeat at 3-6 hours 1

Common Pitfalls to Avoid

1. Don't use traditional CAD risk factors heavily in acute setting—symptoms, ECG, and biomarkers are more important 5, 6

2. Don't rely on risk scores alone without incorporating troponin results and ECG findings 1

3. Don't use GRACE/TIMI for initial triage of undifferentiated chest pain—they were validated in confirmed ACS populations 2

4. Insufficient evidence exists that routine use of risk scores translates into reduced cardiovascular events, though they inform clinical decision-making 1

5. Sex-specific troponin cutoffs may be needed with high-sensitivity assays 1

Evidence Strength Considerations

While multiple risk scores exist, the 2025 guidelines specifically endorse GRACE and TIMI as "well validated and may be useful for helping to guide some therapeutic decisions" 1. The GRACE score's superiority over physician judgment is explicitly stated, though the guidelines acknowledge insufficient evidence that routine scoring reduces adverse events 1. For undifferentiated chest pain, newer evidence supports the HEART score as more accurate than historical tools 2, 3.